123I-MIBG imaging detects cardiac involvement and predicts cardiac events in Churg-Strauss syndrome

  • Yoriko HoriguchiEmail author
  • Yukiko Morita
  • Naomi Tsurikisawa
  • Kazuo Akiyama
Original Article



In Churg-Strauss syndrome (CSS) it is important to detect cardiac involvement, which predicts poor prognosis. This study evaluated whether 123I-metaiodobenzylguanidine (MIBG) scintigraphy could detect cardiac damage and predict cardiac events in CSS.


123I-MIBG scintigraphy was performed in 28 patients with CSS, 12 of whom had cardiac involvement. The early and delayed heart to mediastinum ratio (early H/M and delayed H/M) and washout rate were calculated by using 123I-MIBG scintigraphy and compared with those in control subjects.


Early H/M and delayed H/M were significantly lower and the washout rate was significantly higher in patients with cardiac involvement than in those without and in controls (early H/M, p = 0.0024, p = 0.0001; delayed H/M, p = 0.0002, p = 0.0001; washout rate, p = 0.0012, p = 0.0052 vs those without and vs controls, respectively). Accuracy for detecting cardiac involvement was 86% for delayed H/M and washout rate and 79% for early H/M and B-type natriuretic peptide (BNP). Kaplan-Meier analysis showed significantly lower cardiac event-free rates in patients with early H/M ≤ 2.18 and BNP > 21.8 pg/ml than those with early H/M > 2.18 and BNP ≤ 21.8 pg/ml (log-rank test p = 0.006).


Cardiac sympathetic nerve function was damaged in CSS patients with cardiac involvement. 123I-MIBG scintigraphy was useful in detecting cardiac involvement and in predicting cardiac events.


Churg-Strauss syndrome Cardiac disease Cardiac sympathetic nerve 123I-MIBG Scintigraphy 


Conflicts of interest



  1. 1.
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999;8:179–89.CrossRefPubMedGoogle Scholar
  3. 3.
    Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000;43:414–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Sinico RA, Toma LD, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52:2926–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26–37.CrossRefGoogle Scholar
  6. 6.
    Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951;27:277–301.PubMedGoogle Scholar
  7. 7.
    Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003;361:587–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Bougarit A, Toumelin PL, Pagnoux C, Cohen P, Mahr A, Guern VL, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005;84:323–30.CrossRefGoogle Scholar
  9. 9.
    Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996;75:17–28.CrossRefGoogle Scholar
  10. 10.
    Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques Jr S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987;28:1620–4.PubMedGoogle Scholar
  11. 11.
    Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34:939–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Watanabe K, Takahashi T, Miyajima S, Hirokawa Y, Tanabe N, Kato K, et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med 2002;43:1476–81.PubMedGoogle Scholar
  13. 13.
    Merlet P, Valette H, Dubois-Randé J, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471–7.PubMedGoogle Scholar
  14. 14.
    Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004;92:80–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094–100.CrossRefPubMedGoogle Scholar
  17. 17.
    Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671–8.PubMedGoogle Scholar
  18. 18.
    Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995;36:2138–47.PubMedGoogle Scholar
  19. 19.
    Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Neumann T, Manger B, Schmid M, Kroegel C, Hansch A, Kaiser WA, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009;88:236–43.CrossRefGoogle Scholar
  21. 21.
    Frustaci A, Gentiloni N, Chimenti C, Natale L, Gasbarrini G, Maseri A. Necrotizing myocardial vasculitis in Churg-Strauss syndrome: clinicohistologic evaluation of steroids and immunosuppressive therapy. Chest 1998;114:1484–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Terasaki F, Hayashi T, Hirota Y, Okabe M, Suwa M, Deguchi H, et al. Evolution to dilated cardiomyopathy from acute eosinophilic pancarditis in Churg-Strauss syndrome. Heart Vessels 1997;12:43–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Simantirakis EN, Prassopoulos VK, Chrysostomakis SI, Kochiadakis GE, Koukouraki SI, Lekakis JP, et al. Effect of asynchronous ventricular activation on myocardial adrenergic innervation in patients with permanent dual-chamber pacemakers; an 123I-metaiodobenzylguanidine cardiac scintigraphic study. Eur Heart J 2001;22:323–32.CrossRefPubMedGoogle Scholar
  24. 24.
    Minardo JD, Tuli MM, Mock BH, Weiner RE, Pride HP, Wellman HN, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008–19.PubMedGoogle Scholar
  25. 25.
    Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004;45:155–63.PubMedGoogle Scholar
  26. 26.
    Wassmuth R, Göbel U, Natusch A, Schneider W, Kettritz R, Dietz R, et al. Cardiovascular magnetic resonance imaging detects cardiac involvement in Churg-Strauss syndrome. J Card Fail 2008;14:856–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Pelà G, Tirabassi G, Pattoneri P, Pavone L, Garini G, Bruschi G. Cardiac involvement in the Churg-Strauss syndrome. Am J Cardiol 2006;97:1519–24.CrossRefPubMedGoogle Scholar
  28. 28.
    Morita H, Yokoyama I, Yamada N, Uno K, Nagai R. Usefulness of 18FDG/13N-ammonia PET imaging for evaluation of the cardiac damage in Churg-Strauss syndrome. Eur J Nucl Med Mol Imaging 2004;31:1218.CrossRefPubMedGoogle Scholar
  29. 29.
    Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 2005;11:498–503.CrossRefPubMedGoogle Scholar
  30. 30.
    Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Germano G, Erel J, Kiat H, Kavanagh PB, Berman DS. Quantitative LVEF and quantitative regional function from gated thallium-201 perfusion SPECT. J Nucl Med 1997;38:749–54.PubMedGoogle Scholar
  32. 32.
    Cwajg E, Cwajg J, He ZX, Hwang WS, Keng F, Nagueh SF, et al. Gated myocardial perfusion tomography for the assessment of left ventricular function and volumes: comparison with echocardiography. J Nucl Med 1999;40:1857–65.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yoriko Horiguchi
    • 1
    Email author
  • Yukiko Morita
    • 1
  • Naomi Tsurikisawa
    • 2
  • Kazuo Akiyama
    • 2
  1. 1.Department of CardiologyNational Hospital Organization Sagamihara National HospitalSagamihara CityJapan
  2. 2.Clinical Research Centre for Allergy and RheumatologyNational Hospital Organization Sagamihara National HospitalSagamihara CityJapan

Personalised recommendations